Werewolf Therapeutics, Inc.
HOWL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001785530
In the last 90 days, Werewolf Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 45 institutions reported holding it in 13F filings for Q2 2026, worth $3.91M in total; no superinvestor holds it.
13F holders, Q3 2021
Institutional positions in Werewolf Therapeutics, Inc. as of Sep 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 42
- −3 vs. Q2 2021
- Shares held
- 19.0M
- −750.3K (−3.8%) vs. Q2 2021
- Total value
- $326.2M
- −$18.1M (−5.3%) vs. Q2 2021
- New holders
- 2
- 15 more added
- Sold out
- 5
- 12 more reduced
Compare with Q2 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting HOWL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 45 | $3.91M |
| Q1 2026 | 48 | $11.7M |
| Q4 2025 | 51 | $9.34M |
| Q3 2025 | 62 | $41.6M |
| Q2 2025 | 65 | $24.3M |
| Q1 2025 | 70 | $26.7M |
| Q4 2024 | 73 | $41.7M |
| Q3 2024 | 69 | $68.3M |
| Q2 2024 | 71 | $79.2M |
| Q1 2024 | 61 | $209.0M |
| Q4 2023 | 41 | $106.8M |
| Q3 2023 | 35 | $51.1M |
| Q2 2023 | 36 | $73.3M |
| Q1 2023 | 38 | $62.5M |
| Q4 2022 | 39 | $42.8M |
| Q3 2022 | 44 | $94.5M |
| Q2 2022 | 46 | $78.0M |
| Q1 2022 | 49 | $83.5M |
| Q4 2021 | 51 | $228.3M |
| Q3 2021 | 42 | $326.2M |
| Q2 2021 | 45 | $344.3M |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2021
Shares, value and share of portfolio for each institution holding Werewolf Therapeutics, Inc.; share changes are against Q2 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Financial Perspectives, Inc | 250 | $4.29K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 418 | $7.00K | 0.00% | +366+703.8% | Added |
| Ameritas Investment Partners, Inc. | 593 | $10.0K | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 619 | $11.0K | 0.00% | +132+27.1% | Added |
| Legal & General Group Plc | 736 | $13.0K | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 796 | $14.0K | 0.00% | +277+53.4% | Added |
| Citigroup Inc | 867 | $15.0K | 0.00% | −1,149−57.0% | Reduced |
| Morgan Stanley | 1,514 | $26.0K | 0.00% | +1,247+467.0% | Added |
| UBS Group AG | 1,639 | $28.0K | 0.00% | +639+63.9% | Added |
| STRS Ohio | 1,800 | $30.0K | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 3,848 | $66.0K | 0.00% | −5,504−58.9% | Reduced |
| California State Teachers Retirement System | 4,042 | $69.0K | 0.00% | −6,423−61.4% | Reduced |
| American International Group, Inc. | 4,143 | $71.0K | 0.00% | −98−2.3% | Reduced |
| Deutsche Bank AG | 4,351 | $75.0K | 0.00% | −141−3.1% | Reduced |
| New York State Common Retirement Fund | 14,765 | $253.0K | 0.00% | +1,734+13.3% | Added |
| Levin Capital Strategies, L.P. | 15,000 | $257.0K | 0.03% | +15,000 | New |
| Charles Schwab Investment Management Inc | 19,422 | $334.0K | 0.00% | +3,384+21.1% | Added |
| Evercore Wealth Management, LLC | 21,500 | $369.0K | 0.01% | 00.0% | Unchanged |
| Nuveen Asset Management, LLC | 19,963 | $396.0K | 0.00% | +7,962+66.3% | Added |
| Bank of New York Mellon Corp | 29,789 | $512.0K | 0.00% | +7,576+34.1% | Added |
| Northern Trust Corp | 70,404 | $1.21M | 0.00% | −5,370−7.1% | Reduced |
| State Street Corp | 116,064 | $1.99M | 0.00% | +37,827+48.3% | Added |
| Russell Investments Group, Ltd. | 125,873 | $2.16M | 0.00% | +125,873 | New |
| Geode Capital Management, LLC | 136,472 | $2.34M | 0.00% | +28,294+26.2% | Added |
| Caas Capital Management LP | 162,599 | $2.79M | 0.21% | +62,599+62.6% | Added |
| Vanguard Group Inc | 170,265 | $2.92M | 0.00% | −2,862−1.7% | Reduced |
| Migdal Insurance & Financial Holdings Ltd. | 187,500 | $3.22M | 0.03% | 00.0% | Unchanged |
| Alyeska Investment Group, L.P. | 206,201 | $3.54M | 0.04% | 00.0% | Unchanged |
| Platinum Investment Management Ltd | 213,381 | $3.66M | 0.10% | +6,466+3.1% | Added |
| FMR LLC | 238,500 | $4.09M | 0.00% | −76,500−24.3% | Reduced |
| Nicholas Investment Partners, LP | 296,283 | $5.08M | 0.37% | +1,629+0.6% | Added |
| BlackRock Inc. | 369,961 | $6.35M | 0.00% | +4,098+1.1% | Added |
| PFM Health Sciences, LP | 400,000 | $6.86M | 0.22% | 00.0% | Unchanged |
| Soleus Capital Management, L.P. | 563,396 | $9.67M | 1.51% | 00.0% | Unchanged |
| DC Funds, LP | 589,102 | $10.1M | 39.69% | 00.0% | Unchanged |
| Avidity Partners Management LP | 625,120 | $10.7M | 0.27% | −25,145−3.9% | Reduced |
| Sphera Funds Management Ltd. | 688,475 | $11.8M | 1.17% | −17,819−2.5% | Reduced |
| Adage Capital Partners GP, L.L.C. | 985,448 | $16.9M | 0.03% | −15,149−1.5% | Reduced |
| Deerfield Management Company, L.P. (Series C) | 1,752,787 | $30.1M | 0.59% | −800,000−31.3% | Reduced |
| MPM Oncology Impact Management LP | 2,388,011 | $41.0M | 6.36% | 00.0% | Unchanged |
| MPM Asset Management LLC | 4,284,172 | $73.5M | 17.04% | 00.0% | Unchanged |
| Ra Capital Management, L.P. | 4,291,881 | $73.6M | 1.02% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −37,435−100.0% | Sold out |
| Aristides Capital LLC | 0 | $0 | 0.00% | −25,585−100.0% | Sold out |
| Arena Capital Advisors, LLC- CA | 0 | $0 | 0.00% | −14,958−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −11,300−100.0% | Sold out |
| Capstone Investment Advisors, LLC | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |